WO2001098456A3 - IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA - Google Patents

IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Download PDF

Info

Publication number
WO2001098456A3
WO2001098456A3 PCT/US2001/019157 US0119157W WO0198456A3 WO 2001098456 A3 WO2001098456 A3 WO 2001098456A3 US 0119157 W US0119157 W US 0119157W WO 0198456 A3 WO0198456 A3 WO 0198456A3
Authority
WO
WIPO (PCT)
Prior art keywords
benign prostatic
prostatic hyperplasia
identification
cdnas associated
bph
Prior art date
Application number
PCT/US2001/019157
Other languages
French (fr)
Other versions
WO2001098456A2 (en
Inventor
William E Munger
Prakash Kulkarni
Robert H Getzenberg
Original Assignee
Gene Logic Inc
Japan Tobacco Inc
William E Munger
Prakash Kulkarni
Robert H Getzenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Logic Inc, Japan Tobacco Inc, William E Munger, Prakash Kulkarni, Robert H Getzenberg filed Critical Gene Logic Inc
Priority to AU2001268442A priority Critical patent/AU2001268442A1/en
Publication of WO2001098456A2 publication Critical patent/WO2001098456A2/en
Publication of WO2001098456A3 publication Critical patent/WO2001098456A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates generally to the changes in gene expression in Benign Prostatic Hyperplasia (BPH). The invention relates specifically to two novel human genes which correspond to mRNA species that are differentially expressed in BPH compared to normal prostate tissue.
PCT/US2001/019157 2000-06-20 2001-06-15 IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA WO2001098456A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001268442A AU2001268442A1 (en) 2000-06-20 2001-06-15 Identification of cdnas associated with benign prostatic hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21272600P 2000-06-20 2000-06-20
US60/212,726 2000-06-20

Publications (2)

Publication Number Publication Date
WO2001098456A2 WO2001098456A2 (en) 2001-12-27
WO2001098456A3 true WO2001098456A3 (en) 2002-06-06

Family

ID=22792193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019157 WO2001098456A2 (en) 2000-06-20 2001-06-15 IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

Country Status (2)

Country Link
AU (1) AU2001268442A1 (en)
WO (1) WO2001098456A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268570A1 (en) * 2000-06-16 2001-12-24 Millennium Pharmaceuticals, Inc. 33358, a novel human ankyrin family member and uses thereof
WO2004048408A2 (en) * 2002-11-25 2004-06-10 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Asb-a transcription repressor proteins and nucleic acids and their application in expansion of stem cells
US7700334B2 (en) 2003-08-12 2010-04-20 Lawrence Livermore National Security, Llc Photoswitchable method for the ordered attachment of proteins to surfaces

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 12 March 2000 (2000-03-12), BIRREN ET AL.: "Homo sapiens chromosome 2, clone RP11-637011", XP002907076, accession no. EMBL Database accession no. AC022988 *
DATABASE GENBANK [online] 18 February 2000 (2000-02-18), WAMBUTT ET AL., XP002906930, accession no. EMBL Database accession no. AL049946 *
DATABASE PIR_68 [online] 11 June 1999 (1999-06-11), WAMBUTT ET AL., XP002909078, Database accession no. T08678 *
DATABASE SPTR [online] 1 November 1999 (1999-11-01), WAMBUTT ET AL., XP002909077, accession no. EMBL Database accession no. Q9Y3Y8 *

Also Published As

Publication number Publication date
WO2001098456A2 (en) 2001-12-27
AU2001268442A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001097829A3 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
WO1997036535A3 (en) Biomarkers for detection, diagnosis and prognosis of prostate cancer
WO1999035170A8 (en) Compositions and methods for the treatment of tumor
WO2001002568A3 (en) Human genes and gene expression products
AU2002236507A1 (en) Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
WO1999055858A3 (en) Human nucleic acid sequences obtained from pancreas tumor tissue
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
WO2003032813A3 (en) Methods for the treatment of carcinoma
AUPQ923100A0 (en) Treatment of prostate cancer
WO2001057058A3 (en) Detection of differential gene expression
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2001098456A3 (en) IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
ATE308756T1 (en) METHOD FOR DIFFERENTIATION OF PROSTATE CANCER AND BENEFITS PROSTATE HYPERPLASIA
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO1999046374A3 (en) Human nucleic acid sequences from prostate tumour tissue
WO2004075835A3 (en) Methods for the treatment of renal cell carcinoma
WO2005042741A3 (en) Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions
WO2003008561A3 (en) Genes associated with benign prostatic hyperplasia
WO2002077162A3 (en) Gene (t23490) associated with benign prostatic hyperplasia
WO2002036826A3 (en) Del-1 and benign prostatic hyperplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP